|
Our manufacturing operations are across two
states- Maharashtra and Gujarat. These facilities are built
and operated according to the cGMP. Our three facilities are
approved by the USFDA (two of them are the bulk drug units
at Belapur and Panoli and one is a formulation unit - tablets).
These are also approved by reputed international inspection
agencies for all our major products.
State-of-the-art equipment and instruments give us the edge
to compete globally. We have superior technical & innovation
capabilities courtesy our people, who have repeatedly proven
their ability to rise to challenges. The infrastructure, with
its optimum installed capacities and capital costs, gives
us sustainable competitive cost advantage. All our operations
are supported by fully integrated Supply Chain practices and
ERP systems (JD EDWARD- XE), which enable us to provide a
faster response and service to all our customers across the
world.
As an environmentally responsible organisation, our manufacturing
operations are equipped with state-of-the-art effluent treatment
facilities, including aeration & evaporation systems,
zero discharge facilities. Our Bulk Drug operations and infrastructure
are engineered to optimise solvent and by-product recoveries.
The comprehensive manufacturing services include R&D labs,
pilot plants, technical services, quality control, quality
assurance and regulatory affairs.
Cough Lozenges are made from well researched formulations
under precision manufacturing techniques and stringent quality
control in a state-of-the-art manufacturing plant, run by
a team of highly qualified professionals.
|
 |
This plant is ideally located in an industrial complex with
all infrastructural facilities for optimal operational efficiency.
The plant is fully automated and conforms to current GMP standards
of modular design. |
| |
 |
New IV Facility as per US FDA and EU guidelines
set up in December 2006.
This facility is able to manufacture vials ranging from 10
ml - 500ml |
|
|
USFDA Approved State-of-the-art manufacturing
plant at Panoli (formulation unit- tablets)
|
|
| |
| USFDA Approved State-of-the-art manufacturing
plant at Panoli for Bulk Drug |
| Audits
and Accreditation |
| National Control Laboratory of
Pharmaceutical Products |
Algeria |
| INVIMA |
Colombia |
| MHRA |
Europe |
| Food & Drugs Board |
Ghana |
| State Pharmaceutical Inspection |
Latvia |
| National Drug Authority |
Nigeria |
| Ministry of Health |
Sultanate of Oman |
| Ministry of Health |
Philippines |
| Ministry of Health |
Russia |
| Medicines Control Council |
South Africa |
| FDA |
U.S.A. |
| WHO-GMP certification |
|
|
|
|
|